- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-I17RA/ IL17RA/ CANDF5 monoclonal antibody
Anti-I17RA/ IL17RA/ CANDF5 antibody for FACS & in-vivo assay
Go to IL17RA/IL17RA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-TA009-Ab-1/ GM-Tg-hg-TA009-Ab-2 | Anti-Human IL17RA monoclonal antibody | Human |
| GM-Tg-rg-TA009-Ab-1/ GM-Tg-rg-TA009-Ab-2 | Anti-Rat IL17RA monoclonal antibody | Rat |
| GM-Tg-mg-TA009-Ab-1/ GM-Tg-mg-TA009-Ab-2 | Anti-Mouse IL17RA monoclonal antibody | Mouse |
| GM-Tg-cynog-TA009-Ab-1/ GM-Tg-cynog-TA009-Ab-2 | Anti-Cynomolgus/ Rhesus macaque IL17RA monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-TA009-Ab-1/ GM-Tg-felg-TA009-Ab-2 | Anti-Feline IL17RA monoclonal antibody | Feline |
| GM-Tg-cang-TA009-Ab-1/ GM-Tg-cang-TA009-Ab-2 | Anti-Canine IL17RA monoclonal antibody | Canine |
| GM-Tg-bovg-TA009-Ab-1/ GM-Tg-bovg-TA009-Ab-2 | Anti-Bovine IL17RA monoclonal antibody | Bovine |
| GM-Tg-equg-TA009-Ab-1/ GM-Tg-equg-TA009-Ab-2 | Anti-Equine IL17RA monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-TA009-Ab-1/ GM-Tg-hg-TA009-Ab-2; GM-Tg-rg-TA009-Ab-1/ GM-Tg-rg-TA009-Ab-2; GM-Tg-mg-TA009-Ab-1/ GM-Tg-mg-TA009-Ab-2; GM-Tg-cynog-TA009-Ab-1/ GM-Tg-cynog-TA009-Ab-2; GM-Tg-felg-TA009-Ab-1/ GM-Tg-felg-TA009-Ab-2; GM-Tg-cang-TA009-Ab-1/ GM-Tg-cang-TA009-Ab-2; GM-Tg-bovg-TA009-Ab-1/ GM-Tg-bovg-TA009-Ab-2; GM-Tg-equg-TA009-Ab-1/ GM-Tg-equg-TA009-Ab-2 |
| Products Name | Anti-IL17RA monoclonal antibody |
| Format | mab |
| Target Name | IL17RA |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-IL17RA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-ab-082 | Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody |
| Target Antigen | Products Developing | Multi-species I17RA/ IL17RA/ CANDF5 VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-TA009-Ag-1 | interleukin 17 receptor A (IL17RA) protein |
Target information
| Target ID | GM-TA009 |
| Target Name | IL17RA |
| Gene ID | 23765,16172,312679,709005,486759,101095588,525040,100055511 |
| Gene Symbol and Synonyms | CANDF5,CD217,CDw217,hIL-17R,IL-17RA,IL17R,IL17RA,IMD51,VDw217 |
| Uniprot Accession | Q96F46 |
| Uniprot Entry Name | I17RA_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000177663 |
| Target Classification | Checkpoint-Immuno Oncology, Cytokine Receptor |
The target: IL17RA, gene name: IL17RA, also named as CANDF5, CD217, CDw217, IL-17RA, IL17R, IMD51, hIL-17R. Interleukin 17A (IL17A) is a proinflammatory cytokine secreted by activated T-lymphocytes. It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into neutrophils. The transmembrane protein encoded by this gene (interleukin 17A receptor; IL17RA) is a ubiquitous type I membrane glycoprotein that binds with low affinity to interleukin 17A. Interleukin 17A and its receptor play a pathogenic role in many inflammatory and autoimmune diseases such as rheumatoid arthritis. Like other cytokine receptors, this receptor likely has a multimeric structure. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
